Claims for Patent: 4,816,400

Summary for Patent: 4,816,400

Title:	Basement membrane collagen degrading enzyme and method of purifying same
Abstract:	Basement membrane collagen degrading enzymes are provided which are useful for the detection of malignant cells with metastatic activity. Means for detecting such cells are also provided.
Inventor(s):	Tryggvason; Karl (90230 Oulu 23, FI), Liotta; Lance A. (Bethesda, MD)
Assignee:
Application Number:	07/067,595
Patent Claims:	1. A purified basement membrane collagen degrding enzyme useful for the detection of malignant cells with metastatic activity. 2. The purified basement membrane type IV collagen degrading enzyme of claim 1 wherein the enzyme is labelled with a detectable label. 3. The purified basement membrane type IV degrading enzyme of claim 1 wherein the enzyme is a metal proteinase and the substrate is type IV collagen. 4. The purified basement membrane type IV collagen degrading enzyme of claim 3 wherein the enzyme is labelled with a detectable label. 5. The purified basement membrane type IV collagen degrading enzyme of claim 1 having a molecular weight of about 70,000 and consisting of two polypeptides chains, having a molecular weight of about 62,000 and 68,000 as determined by gel electrophoresis. 6. The purified basement membrane type IV collagen degrading enzyme of claim 5 wherein the enzyme is labelled with a detectable label. 7. A process for isolating and purifying type IV collagenase for immunological utilization comprising the steps of: (a) incubating in a serum-free media tumor cells exhibiting metastatic activity; (b) adding ammonium sulfate to the media to precipitate the medium protein; (c) dissolving the precipitated medium protein in an enzyme buffer containing CaCl.sub.2 ; (d) passing the precipitated protein-enzyme buffer solution through a concanavalin-A agarose chromatography column which binds most of the enzyme activity; (e) eluting the bound enzyme activity with .alpha.-methylglycoside; (f) passing the eluted enzyme activity over a type IV collagen-agarose column equilibrated with enzyme buffer devoid of CaCl.sub.2 ; (g) eluting the bound enzyme activity from the agarose column with an enzyme buffer containing NaCl; (h) passing the eluted enzyme activity over a Bio-Gel A. 0.5 molecular sieve; and, (i) collecting the enzyme activity with an apparent molecular weight of 160,000. 8. The process of claim 7, wherein the enzyme buffer containing CaCl.sub.2 comprises about 0.05 m Tris-HCl about 0.2 m NaCl and about 10 mm CaCl.sub.2 at a pH of about 7.4. 9. The process of claim 7, wherein the tumor cells are murine PMT sarcoma cells. 10. The process of claim 9, wherein the tumor cells are human fibrosarcoma cells.

Details for Patent 4,816,400

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2006-03-28